Pu J, Romanelli R, Zhao B, Azar KM, Hastings KG, Nimbal V, Fortmann SP, Palaniappan LP., Endocrinol Metab Clin North Am. 45(1):205-16. doi: 10.1016/j.ecl.2015.09.013, 2016 Mar 01
Investigators
Kristen Azar, R.N., BSN, MSN/MPH, Investigator, Robert Romanelli, Ph.D., MPH, Associate Scientist
Abstract
This article reviews racial/ethnic differences in dyslipidemia-prevalence of dyslipidemia, its relation to coronary heart disease (CHD) and stroke mortality rates, response to lipid-lowering agents, and lifestyle modification.Asian Indians, Filipinos, and Hispanics are at higher risk for dyslipidemia, which is consistent with the higher CHD mortality rates in these groups.
Statins may have greater efficacy for Asians, but the data are mixed. Lifestyle modifications are recommended.
Culturally-tailored prevention and intervention should be provided to the minority populations with elevated risk for dyslipidemia and considerably more research is needed to determine the best approaches to helping specific subgroups.